{"schema_version":"secwatch.filing_event.v1","accession":"0001555280-26-000021","form_type":"8-K","ticker":"ZTS","cik":"0001555280","company_name":"Zoetis Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.460071+00:00","generated_at":"2026-05-14T21:40:29.370995+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zoetis Q1 revenue flat organic; cuts FY 2026 guidance on softer demand and competition","bullets":["Revenue $2.3B, +3% reported but flat organic; net income $601M ($1.42 EPS), flat YoY.","Adjusted net income $646M ($1.53 EPS), +2% reported, +1% organic; guidance cut: FY rev $9.68-9.96B (2-5% organic growth).","U.S. segment revenue down 8% on competitive pressure and macro price sensitivity; International up 10% organic.","Acquisition of Neogen animal genomics business announced March 2, expected to close H2 2026.","Pipeline includes >12 potential blockbusters; recent approvals in Canada, Thailand, Japan."],"urls":{"canonical":"https://secwatch.observer/filing/0001555280-26-000021","json":"https://secwatch.observer/filing/0001555280-26-000021.json","markdown":"https://secwatch.observer/filing/0001555280-26-000021.md","text":"https://secwatch.observer/filing/0001555280-26-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1555280/000155528026000021/0001555280-26-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1555280/000155528026000021/zts-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:40:29.370995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6d6287c8cfb0ee15197b389600359d20631cd0e9","claim":"Zoetis Inc. reported full year 2026 results: revenue $9.680 - $9.960 Billion, EPS $6.85 to $7.00.","evidence_excerpt":"Revises Full Year 2026 Revenue Guidance to $9.680 - $9.960 Billion with Organic Operational Revenue Growth of 2% to 5% • Revises Full Year 2026 Guidance for Organic Operational Growth in Adjusted Net Income to 2% to 6% • Revises Guidance for Diluted EPS on an Adjusted Basis to $6.85 to $7.00","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1555280/000155528026000021/0001555280-26-000021-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2026"},{"label":"Revenue","value":"$9.680 - $9.960 Billion"},{"label":"EPS","value":"$6.85 to $7.00"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"d6dbb71542bb341113f3fa68e1a3f0ed6da66bc6","claim":"Zoetis Inc. reported Q1 2026 results: revenue $2.3 Billion, net income $601 million, EPS $1.42 per diluted share.","evidence_excerpt":"Zoetis Announces First Quarter 2026 Results • Revenue of $2.3 Billion, Growing 3%, and Net Income of $601 Million, or $1.42 per Diluted Share, Flat and Increasing 6%, Respectively, on a Reported Basis • Adjusted Net Income of $646 Million, or Adjusted Diluted EPS of $1.53","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1555280/000155528026000021/0001555280-26-000021-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q1 2026"},{"label":"Revenue","value":"$2.3 Billion"},{"label":"Net income","value":"$601 million"},{"label":"EPS","value":"$1.42 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}